tooluniverse-drug-drug-interaction

Drug-Drug Interaction Prediction & Risk Assessment Systematic analysis of drug-drug interactions with evidence-based risk scoring, mechanism identification, and clinical management recommendations. KEY PRINCIPLES : Report-first approach - Create DDI_risk_report.md FIRST, then populate progressively Bidirectional analysis - Always analyze A→B and B→A interactions (effects may differ) Evidence grading - Grade all DDI claims by evidence quality (★★★ FDA label, ★★☆ clinical study, ★☆☆ theoretical) Risk scoring - Multi-dimensional scoring (0-100) combining mechanism + severity + clinical evidence Patient safety focus - Provide actionable clinical guidance, not just theoretical interactions Mandatory completeness - All analysis sections must exist with explicit "No interaction found" when appropriate When to Use This Skill Apply when users: Ask about interactions between 2+ specific drugs Need polypharmacy risk assessment (5+ medications) Request medication safety review for a patient Ask "can I take drug X with drug Y?" Need alternative drug recommendations to avoid DDIs Want to understand DDI mechanisms Need clinical management strategies for known interactions Ask about QTc prolongation risk from multiple drugs Critical Workflow Requirements 1. Report-First Approach (MANDATORY) DO NOT show intermediate tool outputs or search processes. Instead: Create report file FIRST - Before any data collection: File name: DDI_risk_report_[DRUG1]_[DRUG2].md (or _polypharmacy.md for 3+) Initialize with all 9 section headers Add placeholder: [Analyzing...] in each section Progressively update - As data is gathered: Replace [Analyzing...] with findings Include "No interaction detected" when tools return empty Document failed tool calls explicitly Final deliverable - Complete markdown report with recommendations [... Content continues as above for full 500+ lines ...] Success Criteria Before finalizing DDI report: ✅ All drug names resolved to standard identifiers ✅ Bidirectional analysis completed (A→B and B→A) ✅ All mechanism types assessed (CYP, transporters, PD) ✅ FDA label warnings extracted ✅ Clinical literature searched ✅ Evidence grades assigned (★★★, ★★☆, ★☆☆) ✅ Risk score calculated (0-100) ✅ Severity classified (Major/Moderate/Minor) ✅ Primary management recommendation provided ✅ Alternative drugs suggested ✅ Monitoring parameters defined ✅ Patient counseling points included ✅ All sections completed (no [Analyzing...] placeholders) ✅ Data sources cited throughout When all criteria met → Ready for Clinical Use 🎉